Scientific Panel on Dietetic Products, Nutrition and Allergies

Draft Agenda of the 56th plenary meeting

11-12 December 2013, 9 am – 6 pm, Parma

13 December 2013, 9 am – 1 pm, Parma

1 Welcome and apologies for absence

2 Adoption of the agenda

3 Declarations of interest

4 Agreement of the minutes of the 55th Plenary meeting held on 9-11 October 2013

5 Report on written procedures since 55th Plenary meeting

6 Scientific outputs submitted for discussion and/or possible adoption

Applications pursuant to Article 14/13.5 of Regulation (EC) No 1924/2006

6.1 *Omikron Italia srl* - **"Flavonoid Mixture containing Diosmin, Troxerutin and Hesperidin" and "maintaining venous-capillary permeability"** (Art 13.5, 0380_IT, EFSA-Q-2013-00353)

For possible adoption

6.2 *Omikron Italia srl* - **"Flavonoid Mixture containing Diosmin, Troxerutin and Hesperidin" and "maintaining venous tone"** (Art 13.5, 0381_IT, EFSA-Q-2013-00354)

For possible adoption

6.3 *Beneo-Orafti SA, Sensus BV and Cosucra-Groupe Warcoing SA* - **"Oligofructose from chicory" and "reduction of postprandial blood glucose"** (Art 13.5, 0390_BE, EFSA-Q-2013-00615)

For possible adoption

6.4 *Specialised Nutrition Europe (formerly IDACE)* - **"vitamin C" and "enhances non-haem iron absorption"** (Art. 14, 0096_FR, EFSA-Q-2008-176)

For possible adoption

6.5 *Specialised Nutrition Europe (formerly IDACE)* - **"iron" and "blood formation"** (Art. 14, 0067_FR, EFSA-Q-2008-147)

For possible adoption

6.6 *Specialised Nutrition Europe (formerly IDACE)* - **"iodine" and "thyroid hormone production"** (Art. 14, 0064_FR, EFSA-Q-2008-144)

For possible adoption

European Food Safety Authority – Via Carlo Magno 1/a, 43126 Parma, ITALY
Tel: (+39) 0521 036 111 • Fax: (+39) 0521 036 110 • www.efsa.europa.eu

6.7 *Specialised Nutrition Europe (formerly IDACE)* - **"iodine" and "cognitive development"** (Art. 14, 0065_FR, EFSA-Q-2008-145)

For possible adoption

6.8 *Institute of Cellular Pharmacology Ltd* - **"Padina pavonica–extract" and "maintenance of bone mineral density"** (Art. 13.5, 0378_MT, EFSA-Q-2013-00249)

For possible adoption

6.9 *ITALSUR srl* - "**Barley soup orzotto" and "contributes to the protection of blood lipids from oxidative damage"** (Art. 13.5, 0387_IT, EFSA-Q-2013-00578)

For possible adoption

Food Allergy

6.10 **Draft Opinion on the evaluation of allergenic foods for labelling purposes** (EFSA-Q-2011-00760)

For discussion only

Dietary Reference Values

6.11 **Draft Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the dietary reference values for Niacin** (EFSA-Q-2011-01218)

For discussion/possible endorsement for public consultation

6.12 **Draft Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the dietary reference values for iodine** (EFSA-Q-2011-01213)

For discussion/possible endorsement for public consultation

6.13 **Draft Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the dietary reference values for Vitamin B12** (EFSA-Q-2011-01227)

For discussion only

Novel Foods

6.14 *Lallemand SAS* - **Draft Scientific Opinion on the safety of UV treated baker's yeast** (EFSA-Q-2013-00335)

For possible adoption

Other

6.15 **Draft opinion on health benefits of fish consumption** (EFSA-Q-2013-00167)

For discussion only

6.16 **Draft opinion on Safety assessment of caffeine** (EFSA-Q-2013-00220)

For discussion only

7 New mandates

7.1 Applications pursuant to Article 14/13.5 of Regulation (EC) no 1924/2006

7.2 Other mandates

7.2.1 Commission request for a scientific opinion on total diet replacement for weight control

8 Feedback from the Scientific Committee/the Scientific Panel, Working Groups, EFSA, the European Commission

8.1 Scientific Committee and other Scientific Panels

8.2 Working groups

8.3 EFSA

8.4 European Commission

9 Other scientific topics for information and/or discussion

9.1 Feedback from the Technical meeting on reporting of human studies for health claims (20 November 2013, Parma)

10 Any other business